When to start and when to stop antifibrotic therapies

Idiopathic pulmonary fibrosis (IPF) is characterised by progressive changes of the lung architecture causing cough and dyspnoea and ultimately leading to lung failure and death. Today, for the first time, two drugs that may reduce the inexorable progression of the disease are available, suggesting t...

Descripción completa

Detalles Bibliográficos
Autores principales: Torrisi, Sebastiano Emanuele, Pavone, Mauro, Vancheri, Ada, Vancheri, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2017
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488637/
https://www.ncbi.nlm.nih.gov/pubmed/28974541
http://dx.doi.org/10.1183/16000617.0053-2017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488637/
https://www.ncbi.nlm.nih.gov/pubmed/28974541
http://dx.doi.org/10.1183/16000617.0053-2017

Ejemplares similares